Logan's Story: The Heart Behind Our Mission
Logan Goodson was the kind of person who made life brighter for everyone around him—a devoted husband, loving son, proud dog dad, and a friend whose kindness knew no bounds. His laughter, his passion for golf, his love for good food and UCF football—these were the things that defined him. But Logan’s life took an unimaginable turn when he was diagnosed with ALK+ Anaplastic Large Cell Lymphoma (ALCL), a rare and aggressive cancer that often strikes children and young adults.
Despite the shock, Logan faced his diagnosis with courage and optimism. Early treatments showed promise, but the disease returned with devastating force, spreading to his nervous system. In the face of limited options, Logan’s care team at MD Anderson pursued an innovative approach, introducing Alectinib, a drug typically used for lung cancer. For a moment, hope returned—his symptoms eased, and his spirit remained strong.
But Logan’s fight was far from over. He needed a stem cell transplant to survive, yet a matching donor never came. Even as the disease advanced into his spinal fluid, Logan never stopped thinking about others. In his hardest moments, he told his wife and doctor:
“We need better treatments. No one should have to go through this.”
That wish became our mission.
Why We Exist
Logan’s story is not just about one life—it’s about the urgent need for progress in T-cell lymphoma research. While B-cell lymphomas have seen major breakthroughs, T-cell lymphomas remain underfunded, understudied, and devastatingly hard to treat. Logan’s experience shines a light on this gap and calls us to action.
Our Commitment
In Logan’s honor, we fight for:
-
Equity in Research: Ensuring diverse representation and reducing disparities in care.
-
Funding Innovation: Supporting studies that unlock the biology of T-cell lymphomas and explore environmental and cultural factors.
-
Collaboration: Bringing researchers together to accelerate new therapies and save lives.
Logan's Legacy
Logan's Legacy:
-
Logan lived with kindness, passion, and resilience. He loved life—whether on the golf course, savoring a great meal, or cheering for UCF. His laid-back spirit and unwavering strength inspire everything we do. This nonprofit exists because of Logan’s wish: to make sure others have hope, options, and a future.
-
Join us in honoring Logan’s life and continuing his fight. Together, we can transform the outlook for T-cell lymphoma patients and bring hope where it’s needed most.
#ForeLogan
T Cell Lymphoma
Understanding Lymphoma: B-cell vs. T-cell
Lymphomas are broadly categorized into Hodgkin and non-Hodgkin lymphomas, with the latter further divided into B-cell and T-cell lymphomas. B-cell lymphomas, being more prevalent, benefit from extensive research and numerous treatment options. However, the same cannot be said for T-cell lymphomas, a group of aggressive diseases with limited funding and therapeutic advancements.​
​
The Unseen Struggle of T-Cell Lymphomas
While B-cell lymphomas have witnessed significant progress, T-cell lymphomas, particularly the deadly manifestations, remain a formidable challenge. With a myriad of subtypes, research efforts are slow, and treatment options are scarce. Among the rare but highly lethal cases is the spread of T-cell lymphomas to the neurologic system, a devastating complication with limited therapeutic avenues.​
​
Challenges We Face
Several factors hinder the progress in T-cell lymphoma research. The vast array of T-cell lymphoma types, coupled with the scarcity of cases globally, presents a unique challenge. Moreover, inadequate funding opportunities have impeded substantive and innovative breakthroughs. It is time to confront these challenges head-on and pave the way for a brighter future.
​
​Transforming Lives Affected by T-Cell Lymphomas
​​Representation and Equity: We strive to enhance representation from minority populations within T-cell lymphoma research. By addressing relevant questions, we aim to reduce disparities in care and ensure that every patient, irrespective of their background, receives the attention and resources they deserve.​
​
Research Funds for Understanding Biology: We are committed to providing essential research funds to develop studies that delve into the intricate biology of T-cell lymphomas. Our focus extends beyond the disease itself, exploring the roles of environmental, lifestyle, and cultural factors in shaping variations in T-cell lymphoma incidences across diverse populations.​
​
Engaging the Research Community: Collaboration is the cornerstone of progress. We actively engage with the research community to bring cutting-edge tools and methodologies to the forefront. By fostering collaboration and innovation, we strive to improve therapies and outcomes for T-cell lymphoma patients—a population with a high unmet need.
